AIM Financials: AIM ImmunoTech Inc AI Analysis

Home

Stock

AIM

Financials

AIM Financial

AIM ImmunoTech Inc

$0.97

1.51%

$0.01

At close: Mar 24, 16:00:00 GMT-4

$0.96

-0.15%

$0

Post-market: Mar 24, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.956

Open

$0.956

Day's Range

$0.9081 - $1.04

52 week range

$0.61 - $34.91

Volume

1.0M

Avg.Volume

4.7M

Dividend yield

EPS (TTM)

-24.68

Market Cap

$4.0M

What is AIM?

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

AIM Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
Selling, General & Admin	11	14	21	13	8	8
Research & Development	4	5	10	6	7	5
Operating Expenses	16	19	32	20	16	14
Other Non Operating Income (Expenses)	--	--	--	0	0	0
Pretax Income	-16	-17	-28	-19	-19	-14
Income Tax Expense	--	--	--	--	--	--
Net Income	-16	-17	-28	-19	-19	-14
Net Income Growth	-43%	-39%	47%	0%	36%	56%
Shares Outstanding (Diluted)	0.75	0.56	0.48	0.48	47.34	31.84
Shares Change (YoY)	-99%	15%	1%	-99%	49%	774%
EPS (Diluted)	-21.29	-30.91	-59.61	-40.47	-0.4	-0.45
EPS Growth	3,917%	-48%	47%	9,917%	-11%	-82%
Free Cash Flow	-11	-14	-21	-16	-14	-10
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	0%	0%	0%
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-16	-19	-31	-19	-17	-15
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-16	-19	-31	-19	-17	-15
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	--

Follow-Up Questions

What are AIM ImmunoTech Inc's key financial statements?



According to the latest financial statement (Form-10K), AIM ImmunoTech Inc has a total asset of $8, Net loss of $-17

What are the key financial ratios for AIM?



AIM ImmunoTech Inc's Current ratio is 0.88, has a Net margin is 0, sales per share of $0.

How is AIM ImmunoTech Inc's revenue broken down by segment or geography?



AIM ImmunoTech Inc largest revenue segment is Ampligen and Other Drugs, at a revenue of 170,000 in the most earnings release.For geography, United States is the primary market for AIM ImmunoTech Inc, at a revenue of 170,000.

Is AIM ImmunoTech Inc profitable?



no, according to the latest financial statements, AIM ImmunoTech Inc has a net loss of $-17

Does AIM ImmunoTech Inc have any liabilities?



yes, AIM ImmunoTech Inc has liability of 9

How many outstanding shares for AIM ImmunoTech Inc?



AIM ImmunoTech Inc has a total outstanding shares of 0.65

AIM ImmunoTech Inc (AIM) Financial

AIM Stock Price Chart